Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

European Drug Development Project Targets Gram-negative Bacteria

By BiotechDaily International staff writers
Posted on 25 Feb 2014
Image: Microscopic image of gram-negative Pseudomonas aeruginosa bacteria (pink-red rods) (Photo courtesy of Wikimedia Commons).
Image: Microscopic image of gram-negative Pseudomonas aeruginosa bacteria (pink-red rods) (Photo courtesy of Wikimedia Commons).
A consortium of European universities, research institutes, and biopharmaceutical companies has been established to discover and develop novel new antibiotics, especially for treatment of gram-negative bacterial infections.

The ENABLE (European Gram-Negative Antibacterial Engine) project brings together more than 30 European universities and companies, in a six-year program funded by the Innovative Medicines Initiative (Brussels, Belgium), a joint undertaking between the European Union and the pharmaceutical industry association EFPIA (European Federation of Pharmaceutical Industries and Associations – Brussels, Belgium).

The ENABLE project, which is the third within the ND4BB (New Drugs for Bad Bugs) series, spans 13 countries and charges the 32 partners with the mission of establishing a significant antibacterial drug discovery platform for the progression of research programs through discovery and Phase 1 clinical trials.

The primary target of the ENABLE project is gram-negative bacteria. Medically relevant gram-negative bacilli include a multitude of species. Some of them cause primarily respiratory problems (Hemophilus influenzae, Klebsiella pneumoniae, Legionella pneumophila, Pseudomonas aeruginosa), primarily urinary problems (Escherichia coli, Proteus mirabilis, Enterobacter cloacae, Serratia marcescens), and primarily gastrointestinal problems (Helicobacter pylori, Salmonella enteritidis, Salmonella typhi).

One of the several unique characteristics of these bacteria is the structure of the outer membrane. The outer leaflet of the membrane comprises a complex lipopolysaccharide (LPS) whose lipid portion acts as an endotoxin. If LPS enters the circulatory system, it causes a toxic reaction, with the sufferer developing a high temperature, high respiration rate, and low blood pressure. This may lead to endotoxic shock, which can be fatal. This outer membrane protects the bacteria from several antibiotics, dyes, and detergents that would normally damage either the inner membrane or the cell wall's (peptidoglycan). The outer membrane provides these bacteria with resistance to antibacterial agents such as lysozyme and penicillin.

MEDINA (Granada, Spain), one of the participants in the ENABLE project, is an independent nonprofit research and development organization established jointly by the pharmaceutical company Merck Sharp and Dohme, the government of Andalucia, and the University of Granada. Its researchers are actively seeking new molecules from its proprietary natural product libraries to develop new medicines that respond to unmet medical needs.

“MEDINA brings to the project one of the novel antibiotic molecules that will be developed within this partnership. Our participation in this program represents a fantastic opportunity to jointly develop one of our most advanced compounds in our pipeline,” said Dr. Olga Genilloud, scientific director of MEDINA. “MEDINA offers a unique and longstanding expertise in drug discovery. We are committed with the global research effort for the discovery of new antibiotics, as continuity of a long history of success which has resulted in some of the most important breakthrough drugs available to patients today.”

Related Links:

Innovative Medicines Initiative
European Federation of Pharmaceutical Industries and Associations
MEDINA



Channels

Genomics/Proteomics

view channel
Image: The TheraCyte cell encapsulation device (Photo courtesy of TheraCyte, Inc.).

Encapsulated Human-Insulin-Producing Progenitor Cells Cure Diabetes in Mouse Model

A breakthrough system that allows subcutaneous implantation of encapsulated immature pancreatic cells (beta progenitor cells) was shown to produce enough insulin to correct the symptoms of diabetes in a mouse model.... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Lab Technologies

view channel
Image: Diagram of the apparatus for testing drug solubility (Photo courtesy of the University of Huddersfield).

Novel Apparatus Mimics the Human Digestive System for Oral Drug Studies

A team of British drug developers has created an instrument that mimics the human digestive system, which will allow them to accurately determine how orally-administered medications are dissolved and then absorbed.... Read more

Business

view channel

Analytical Sciences Trade Fair Declared a Rousing Success

Organizers of this year's 24th "analytica" biosciences trade fair have reported significant increases in both the number of visitors and exhibitors compared to the 2012 event. The analytica trade fair for laboratory technology, analysis, and biotechnology has been held at the Munich (Germany) Trade Fair Center every... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.